
Heart Failure - Pipeline Insight, 2024
Description
Heart Failure - Pipeline Insight, 2024
DelveInsight’s, “Heart Failure - Pipeline Insight, 2024” report provides comprehensive insights about 75+ companies and 90+ pipeline drugs in Heart Failure pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Heart Failure: Overview
Heart failure (HF) is a syndrome caused by structural and functional defects in myocardium resulting in impairment of ventricular filling or the ejection of blood. The most common cause for HF is reduced left ventricular myocardial function. Major pathogenic mechanisms leading to HF are increased hemodynamic overload, ischemia-related dysfunction, ventricular remodeling, excessive neuro-humoral stimulation, abnormal myocyte calcium cycling, excessive or inadequate proliferation of the extracellular matrix, accelerated apoptosis and genetic mutations. Heart failure is a pathological condition in which the heart is unable to pump enough blood to the rest of the body, because it is either unable to fill with a sufficient volume of blood or unable to generate sufficient force to pump out enough blood. Dysfunction of the pericardium, myocardium, endocardium, heart valves or great vessels alone or in combination is also associated with HF.
Heart failure can severely decrease the functional capacity of a patient and increase mortality risk. It is imperative to diagnose and effectively treat the disease to prevent recurrent hospitalizations, improve quality of life, and enhance patient outcomes. The treatment of heart failure requires a multifaceted approach involving patient education, optimal medical regimen to improve cardiac contractility, and prevention/limitation of exacerbations. The cardinal manifestations of HF are dyspnea and fatigue, which may limit exercise tolerance and fluid retention, which may lead to pulmonary and/or splanchnic congestion and/or peripheral edema. Heart failure, remains a stubborn problem and is now considered to be the greatest challenge in cardiovascular medicine and surgery.
“Heart Failure - Pipeline Insight, 2024"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure pipeline landscape is provided which includes the disease overview and Heart Failure treatment guidelines. The assessment part of the report embraces, in depth Heart Failure commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure.
This segment of the Heart Failure report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Heart Failure Emerging Drugs
- Tirzepatide: Eli Lilly and Company
- Finerenone (BAY94-8862): Bayer
The initiation of the Phase III FINEARTS-HF study (FINerenone trial to investigate Efficacy and sAfety superioR to placebo in paTientS with Heart Failure) builds upon the robust Phase II studies ARTS-HF and ARTS-DN which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease, respectively. Data from the Phase II study program ARTS were presented at ESC Congress 2015 in London.
- CardiAMP Cell Therapy: BioCardia
- HU 6: Rivus Pharmaceuticals
Further product details are provided in the report……..
Heart Failure: Therapeutic Assessment
This segment of the report provides insights about the different Heart Failure drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Heart Failure
Phases
DelveInsight’s report covers around 90+ products under different phases of clinical development like
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Intra-articular
- Intraocular
- Intrathecal
- Intravenous
- Ophthalmic
- Oral
- Parenteral
- Subcutaneous
- Topical
- Transdermal
- Molecule Type
- Oligonucleotide
- Peptide
- Small molecule
- Product Type
Heart Failure: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Heart Failure therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure drugs.
Heart Failure Report Insights
- Heart Failure Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Heart Failure drugs?
- How many Heart Failure drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Heart Failure and their status?
- What are the key designations that have been granted to the emerging drugs?
- Zensun (Shanghai) Sci & Tech
- Windtree Therapeutics
- TreeFrog Therapeutics
- Torrent Pharmaceuticals
- Tenaya Therapeutics
- Tasly Pharmaceuticals
- Sulfagenix
- Stealth BioTherapeutics
- SQ Innovation
- Shanghai Hongyitang Biopharmaceutical Technology
- scPharmaceuticals
- Sardocor
- Sana Biotechnology
- Salubris Biotherapeutics
- Roche
- Rivus Pharmaceuticals
- Ribomic
- Renova Therapeutics
- Relaxera
- Regeneron Pharmaceuticals
- Recardio
- Quantum Genomics
- Procella Therapeutics
- Precigen
- Pfizer
- Paradigm biopharmaceuticals
- Palatin Technologies
- Orizuru Therapeutics
- Olatec Therapeutics
- Novo Nordisk
- Metcela
- Mesoblast Inc.
- Merck & Co
- Lexicon Pharmaceuticals
- Janssen Research & Development
- Ionis Pharmaceuticals
- InvivoSciences
- Intra-Cellular Therapies
- Innolife
- Imbria Pharmaceuticals
- Imara Inc
- Hyloris Pharmaceuticals
- Help Therapeutics
- Heartseed
- HAYA Therapeutics
- GlaxoSmithKline
- GB Sciences
- Fujifilm Corporation
- Evotec SE
- Eli Lilly and Company
- Edgewise Therapeutics
- DiNAQOR
- Cytokinetics
- CUORiPS
- Chong Kun Dang
- Cardurion Pharmaceuticals
- Cardior Pharmaceuticals
- Cardiol Therapeutics
- CardioCell
- Bristol-Myers Squibb
- Boryung Pharmaceutical
- BlueRock Therapeutics
- BioCardia
- BIAL
- Berlin Cures
- BenevolentAI
- Bayer
- Athersys
- AstraZeneca
- Asklepios Biopharmaceutical
- Antlia Biosciences
- AnaCardio
- AliveGen
- Actelion Pharmaceuticals
- Recombinant Human Neuregulin-1β (rhNRG-1)
- Istaroxime
- SERCA2a activators
- hiPSC-derived cardiac cells
- TRC 041266
- TN-301
- AAV-Based Research Project
- DWORF
- Qishenyiqi Dripping Pills
- SG1002
- Elamipretide
- SQIN-01
- TSG-01
- Furoscix
- SRD-001
- SC 187
- JK-07
- Pirfenidone
- HU6
- RBM-003
- RT 100
- Relaxin-2
- REGN5381
- REC 02
- Firibastat
- Heart Failure Research Project
- PROC-001
- INXN-4001
- Sildenafil citrate
- APD-418
- Prazosin hydrochloride
- Pentosan Polysulfate Sodium (PPS)
- PL 3994
- IPSC-derived cardiomyocyte
- Dapansutrile
- Semaglutide
- MTC001
- Rexlemestrocel-L (Revascor)
- Ertugliflozin
- Sotagliflozin
- Rivaroxaban
- IONIS-AGT-LRx
- IVS201
- Lenrispodun
- INL 1
- IMB-101
- IMR-687
- Milrinone
- Metolazone IV
- HiCM-188
- HS-001
- Antisense oligonucleotide based therapy
- GSK3884464
- Research programme: heart failure therapeutics
- iPSC-derived cardiac progenitor cells
- IPSC-Based Tissue Therapy
- Tirzepatide
- LY3461767
- EDG 002
- DINA-007/A
- DINA-007/B
- Omecamtiv mecarbil
- CK-136
- IPSC-derived cell
- CKD-349
- CRD 733
- Research programme: cardiovascular therapies
- CRD-102
- CDR132L
- CardiolRx
- Allogeneic Mesenchymal Bone Marrow Cells
- Mavacamten
- BMS-986231
- FA relaxin
- ROMK inhibitor
- BR1016C
- BR1016A
- Research programme: induced pluripotent stem cell therapeutics
- CardiAMP cell therapy
- CardiALLO Cell Therapy
- Zamicastat
- BC-007
- Research programme: therapeutics
- Finerenone (BAY 94-8862)
- Pecavaptan
- MultiStem cell therapy
- AZD4831
- AZD 9977
- AZD-8601
Key Products
Table of Contents
300 Pages
- Introduction
- Executive Summary
- Heart Failure : Overview
- Introduction
- Classification
- Causes and Risk factors
- Diagnosis
- Etiology
- Pathogenesis
- Signs and Symptoms
- Treatment
- Pipeline Therapeutics
- Comparative Analysis
- Therapeutic Assessment
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
- Assessment by Product Type
- Assessment by Stage and Product Type
- Heart Failure – DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Comparative Analysis
- Tirzepatide: Eli Lilly and Company
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Comparative Analysis
- HU 6: Rivus Pharmaceuticals
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- Comparative Analysis
- HiCM 188: Help Therapeutics
- Product Description
- Research and Development
- Product Development Activities
- Drug profiles in the detailed report…..
- Inactive Products
- Comparative Analysis
- Heart Failure - Collaborations Assessment- Licensing / Partnering / Funding
- Heart Failure - Unmet Needs
- Heart Failure - Market Drivers and Barriers
- Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.